CPC G01N 33/5058 (2013.01) [C12N 5/0622 (2013.01); C12N 5/0696 (2013.01); C12Q 1/6883 (2013.01); G16H 50/30 (2018.01); A61K 31/7105 (2013.01); C07K 16/28 (2013.01); C12N 2310/141 (2013.01); C12N 2310/20 (2017.05); G01N 2570/00 (2013.01); G01N 2800/285 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/2835 (2013.01)] | 7 Claims |
1. A method of determining if abnormal expression of a Chitinase-3-like 1 protein (CHI3L1) gene and/or a CHI3L1 receptor is associated with a neurological disease, comprising:
differentiating astrocytes from induced pluripotent stem cells (iPSCs) obtained from one or more healthy control subjects;
differentiating astrocytes from iPSCs obtained from a subject suffering from the neurological disease;
performing a transcriptome analysis of the astrocytes derived from the subject suffering from the neurological disease and a transcriptome analysis of the astrocytes derived from the one or more healthy control subjects;
comparing the results of both transcriptome analyses to determine if the CHI3L1 gene and/or the CHI3L1 receptor are substantially differentially expressed in the subject suffering from the neurological disease compared to the one or more healthy subjects; and if the CHI3L1 gene and/or a CHI3L1 receptor are differentially expressed; and
correcting the expression of the CHI3L1 gene and/or the CHI3L1 receptor,
wherein complete or partial restoration of one or more phenotypes of the neurological disease after correcting expression of the CHI3L1 gene and/or the CHI3L1 receptor indicates that the CHI3L1 gene and/or the CHI3L1 receptor are associated with the neurological disease.
|